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Accurate interpretation of elevated amylase levels is essen-
tial, especially for patients presenting with an overlapping 
pancreatic or liver disease or for patients with a history of 
these diseases [1]. In this study, we have described an un-
usual case of macroamylasemia that occurred immediately 
after acute pancreatitis. On March 9, 2010, a 56-yr-old Ko-
rean man was admitted to the emergency department be-
cause of confusion and delirium. He had previously been 
hospitalized for 4 months because of alcoholic cirrhosis and 
had been discharged 5 days prior to this admission. During 
the 4-month hospitalization, he had received treatment for 
esophageal variceal bleeding and acute pancreatitis. At that 
time, his serum amylase levels and lipase levels were 1,171 
U/L and 298 U/L, respectively. Abdominal computed to-
mography images showed mild swelling of the pancreas and 
a cystic lesion (1.5 cm) in the pancreatic head (Fig. 1). The 
patient received therapy for acute pancreatitis. Although he 
showed improvement in symptoms and radiological find-
ings at the time of discharge, on March 4, 2010, the serum 
amylase levels had increased to 1,882 U/L (Fig. 2). Five days 
later, the patient was readmitted because of altered mental 
status. Physical examinations revealed no abdominal pain 
and no rebound tenderness. The results of the blood bio-
chemistry tests were as follows: total protein, 9.2 g/dL; albu-
min, 2.9 g/dL; amylase, 2,232 IU/L (25-125 IU/L); lipase, 61 
IU/L (5.5-58 IU/L); total bilirubin, 2.39 mg/dL; direct biliru-
bin, 1.63 mg/dL; AST, 48 IU/L; ALT, 30 IU/L; alkaline phos-
phatase (ALP), 64 IU/L; gamma-glutamyl transpeptidase 
(GGT), 29 IU/L; and ammonia, 141 mg/dL. The serological 
tests yielded the following results: IgG, 3,850 mg/dL (700-
1,600 mg/dL) and IgA, 664 mg/dL (70-400 mg/dL). After 
readmission, the urine amylase level was 54 IU/L (1-352 IU/
L), and the amylase-creatinine clearance ratio (ACCR) was 
calculated to be 0.07%. Macroamylasemia was diagnosed on 
the basis of these findings. Serum amylase isoenzyme elec-
trophoresis showed that the proportions of P-type and S-
type amylases were 75.3% and 24.7%, respectively. Capillary 
serum protein electrophoresis revealed polyclonal gammop-
athy with a beta-gamma bridge pattern, which is a typical 
pattern in liver cirrhosis (Fig. 3). The patient’s mental status 
returned to normal, and he is still in the hospital for contin-
ued management of liver cirrhosis.
Macroamylasemia has been reported in 2.5% of the pa-
tients with hyperamylasemia and in 1% of the general pop-
ulation; approximately 0.4% of the cases in the general pop-
ulation occur in the West [2, 3]. Increased amylase and/or 
lipase activities were seen in 8% of the patients without 
pancreatic diseases [4]. In the previous reports, macroamy-
lasemia was mainly reported in patients with disturbed hu-
moral immunity, such as those with celiac disease, multiple 
myeloma, HIV infection, ulcerative colitis, and rheumatoid 
arthritis [2, 3, 5-8]. One of the predisposing conditions for 
macroamylasemia is a polyclonal increase in immunoglob-
ulins (Ig). Some studies have reported that macroamylase-
mia may decrease or resolve when these underlying dis-
eases are treated, and that the risk for autoimmune or lym-
phoproliferative diseases is higher in macroamylasemia 
with light-chain restriction in Ig-enzyme complexes [2, 9].
Complex formation with IgA-type immunoglobulins was 
reported in 92% of the patients with macroamylasemia [2, 
9]. Liver cirrhosis is known to be a condition that increases 
IgA production through the following mechanism: Serum 
albumin concentrations are greatly reduced by increased al-Cho SY, et al.  •  Macroamylasemia and Acute Pancreatitis
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bumin degradation as well as decreased synthesis. To main-
tain plasma oncotic pressure, the shortage in albumin is 
compensated by a polyclonal increase in Igs. This polyclonal 
gammopathy involves all Igs such that an increase of IgA in 
the beta region shows beta-gamma bridging [10]. Although 
there is no information on the Ig subtypes that are involved 
in the formation of macroamylase, polyclonal gammopathy 
might contribute to an increased propensity between amy-
lase and Ig to form macroenzymes.
The latent period for the clinical appearance of macroam-
ylasemia varies from several weeks to months [2]. Hyper-
amylasemia persisted in our patient even though the symp-
toms and radiological findings of acute pancreatitis showed 
clinical improvement. Therefore, although macroamylase-
mia was diagnosed only a few weeks prior to presentation, 
it persisted even after the resolution of acute pancreatitis.
To avoid unnecessary laboratory tests, misdiagnosis, and 
overtreatment, it is essential to differentiate macroamylase-
mia from hyperamylasemia, particularly in patients without 
corroborating clinical evidence for hyperamylasemia. 
Therefore, we suggest that patients with macroamylasemia 
of unknown origin should be carefully assessed since they 
may have an underlying condition characterized by Ig over-
production even though they may present with persistent 
hyperamylasemia.
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Fig. 1. Findings of abdominal computed tomography performed when the patient showed acute pancreatitis. A cystic lesion (arrows, 1.5 cm) in the pancreatic 
head region (A) and mild swelling of the pancreas (B) are observed.
Fig. 2. Trends in the serum amylase and lipase levels from the time of diag-
nosis of acute pancreatitis (*) to the time of diagnosis of macroamylasemia 
(**). Serum amylase levels are high for about 4 months, while lipase levels 
fall near the upper reference limit. Macroamylasemia may occur when lipase 
level returned to normal, unlike the amylase level, which was sustained at a 
high level.
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Fig. 3. Serum amylase isoenzyme electrophoresis (A) and capillary electrophoresis (B and C). (A) The P-type amylase level increased to 1,664.13 IU/L (75.30% of 
the total amylase concentration). The S-type amylase level is within the reference interval (545.87 IU/L; 24.70%). Serum protein capillary electrophoresis (B) and 
immunotyping (C) show polyclonal gammopathy with a beta-gamma bridge pattern, which is a typical pattern in patients with liver cirrhosis. In immunoglobu-
lin quantification, the estimated IgG and IgA levels were 3,850 mg/dL (reference interval, 700-1,600 mg/dL) and 664 mg/dL (reference interval, 70-400 mg/dL), 
respectively.
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